Evidence map›Paper›PMID 34298478›Full record

ArticleMultiple sclerosis and related disorders2021

Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.

Jelena Drulovic, Jovana Ivanovic, Vanja Martinovic, Olivera Tamas, Nikola Veselinovic, Danica Cujic, Marija Gnjatovic, Sarlota Mesaros, Tatjana Pekmezovic

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  4. Article
  5. Review
  6. Cladribine tablets in the new multiple sclerosis era.Therapeutic advances in neurological disorders · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Observational
  11. Review
  12. Nanoparticles in clinical trials of COVID-19: An update.International journal of surgery (London, England) · 2022
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jelena DrulovicClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia. Electronic address: drulovicjelena@gmail.com.
Jovana IvanovicClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Serbia.
Vanja MartinovicClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Serbia.
Olivera TamasClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia.
Nikola VeselinovicClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia.
Danica CujicInstitute for Application of Nuclear Energy, University of Belgrade, Banatska 31b, 11080 Belgrade, Serbia.
Marija GnjatovicInstitute for Application of Nuclear Energy, University of Belgrade, Banatska 31b, 11080 Belgrade, Serbia.
Sarlota MesarosClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia.
Tatjana PekmezovicInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, Visegradska 26A, 11000 Belgrade, Serbia.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt has been generally accepted that people with MS (PwMS) should be vaccinated against COVID-19. The aim of our investigation was to evaluate the humoral response to natural SARS-CoV-2 infection and to two COVID-19 vaccines (BNT162b2 Pfizer-BioNTech and Beijing/Sinopharm BBIBP-CorV) in our cohort of PwMS under high efficacy disease modifying therapies (DMTs), cladribine and alemtuzumab.

methodsTwenty two PwMS treated at the Clinic of Neurology, in Belgrade, who developed COVID-19 and/or were vaccinated against SARS-CoV-2, during treatment with cladribine and alemtuzumab, were included. Out of 18 patients treated with cladribine, 11 developed COVID-19, and 11 were vaccinated against SARS-CoV-2 (four with mRNA vaccine, 7 with Sinopharm). Four MS patients under alemtuzumab were vaccinated against SARS-CoV-2; three with mRNA, and one with Sinopharm vaccine. SARS-Cov-2 IgG response was measured using ELISA anti-spike protein-based serology (INEP, Belgrade, Serbia).

resultsAll 7 patients under cladribine treatment who suffered from COVID-19, developed IgG antibodies, 2.0-5.5 months after last symptoms. All four (100%) patients under cladribine who were vaccinated with Pfizer-BioNTech vaccine, and three out of seven (42.9%) vaccinated with Sinopharm, developed antibodies. All 4 patients under alemtuzumab developed antibodies after vaccination. In all cases, seroprotection occurred, irrespective of timing of vaccination and absolute lymphocyte count.

conclusionOur findings in a small number of highly active PwMS in whom, lymphodepleting, immune reconstitution therapies, were applied in order to successfully manage MS, indicate that in a number of these patients it was possible to develop at the same time seroprotection in these patients after COVID-19 vaccination in these complex circumstances.

Indexed as

COVID-19Immune ReconstitutionMultiple SclerosisBNT162 VaccineCOVID-19 VaccinesHumansSARS-CoV-2BNT162 VaccineCOVID-19 VaccinesalemtuzumabcladribineCOVID-19humoral responsemultiple sclerosisPfizer-BioNTechSinopharmvaccination

Identifiers

PMID34298478
PMCPMC8280377
OpenAlexW3184702704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.